Skin Cancer Scanning Ltd. (SCS) is a medical device company focused on developing and marketing a non-invasive, painless test that can be completed quickly in the doctor’s office. Its objective is to improve early detection and more accurately diagnose skin cancer and precancerous lesions.
We believe SkinScan 650 will enable physicians to diagnose skin cancer at an earlier, most curable stage with fewer false positive biopsies. This would reduce both treatment costs and the number of unnecessary biopsies, and improve quality of life.
The devise is dedicated to diagnosing lesions by the use of light reflectance in the Visual and Infra Red range of the spectrum. In addition, our technology has the ability to diagnose non-melanoma skin cancers with a high-sensitivity rate and a specificity rate, which at this, not final, stage of development, is more accurate than the GP and the unaided dermatologist. Used correctly ,by the GP and the Dermatologist ,our device, SkinScan 650 will significantly improve the entire diagnostic capabilities in diagnosing skin cancer.
To date we have completed two stages of clinical trials at the Rabin Medical Center in Petah Tikva, Israel. These trials validated our Non Melanoma Skin Cancer (NMSC) capabilities resulting with a 92.4% sensitivity rate. The Second stage medical trials, which provided these results, were blinded and were completed in accordance with the Declaration of Helsinki criteria.
We , at SCS, are now focusing our entire facilities on completing the development of SkinScan 650 and enabling it to diagnose Melanoma Skin Cancer (MSC), with improved capabilities
We expect the Hybrid Device, SkinScan 650, operating in the visual and the infra red range of the spectrum, to be fully developed in the near future.
This will enable diagnosis of MSC and NMSC to be achieved with a higher sensitivity rate than the present results, in both MSC and NMSC.